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Enteroviruses are suspected to contribute to insulin-producing b cell loss and hyperglycemia-induced dia-
betes. However, mechanisms are not fully defined. Here, we show that coxsackievirus B type 4 (CVB4) infec-
tion in human islet-engrafted mice and in rat insulinoma cells displays loss of unconventional prefoldin RPB5
interactor (URI) and PDX1, affecting b cell function and identity. Genetic URI ablation in the mouse pancreas
causes PDX1 depletion in b cells. Importantly, diabetic PDX1 heterozygous mice overexpressing URI in b
cells are more glucose tolerant. Mechanistically, URI loss triggers estrogen receptor nuclear translocation
leading to DNA methyltransferase 1 (DNMT1) expression, which induces Pdx1 promoter hypermethylation
and silencing. Consequently, demethylating agent procainamide-mediated DNMT1 inhibition reinstates
PDX1 expression and protects against diabetes in pancreatic URI-depleted mice . Finally, the b cells of hu-
man diabetes patients show correlations between viral protein 1 and URI, PDX1, and DNMT1 levels. URI and
DNMT1 expression and PDX1 silencing provide a causal link between enterovirus infection and diabetes.
INTRODUCTION
Glucose homeostasis is maintained through tight dynamic regu-
lation of insulin expression by pancreatic b cells, dysfunction or
alteration of which can lead to high blood sugar, and hence type
1 or 2 diabetes mellitus (T1D or T2D) or maturity-onset diabetes
of the young (MODY).1–3 Notably, T1D is attributed to b cell-spe-
cific antibodies (first-line predictive and diagnostic markers) and
T cell-mediated autoimmune responses. However, the presence
of autoantibodies is not always accompanied by symptoms and
the presence of immune-infiltrated cells in the endocrine
pancreas of T1D patients, as for instance in idiopathic T1D, char-
acterized by an almost complete insulin deficiency without evi-
dence of autoimmune responses.4,5 Moreover, the susceptibility
of antigen recognition through polymorphisms in the human
leukocyte antigen (HLA) loci within the major histocompatibility
complex, which accounts for half of the susceptibility risk of
T1D, does not explain the steep increase in T1D prevalence
that has occurred in the last 30 years.2 Low heritability suggests
that T1D is probably modulated by environmental factors.1 For
example, early-onset obesity increases the glucose-sensing
threshold for insulin production,6,7 suggesting that nutrient over-
load can promote T1D (probably the idiopathic type), and some
pathological agents have suggested causal responsibility.8,9
Moreover, it has been recently proposed that viral transcription
factors operating across risk loci within disease phenotypes
may play major roles in autoimmune disorders.10 Accordingly,
several studies suggest that enteroviruses (particularly coxsack-
ievirus serotypes) may be critical triggers of T1D, either through
direct cytolytic effects and gradual b cell destruction or
bystander activation of other factors participating in the T1D pro-
cess.1,2,8,11–13 More important, fresh pancreatic tissue analysis
of patients with new-onset T1D has revealed the presence of
enterovirus-positive cells in the endocrine compartment advo-
cating for an etiological role of viral infection in T1D.14 In this
context, antiviral drugs and vaccine trials have been proposed
for the prevention of T1D.15 However, the mechanisms through
which b cell alterations induced by viral infections can affect in-
sulin production remain unknown.
Pancreatic and duodenal homeobox 1 (PDX1) is a core tran-
scription factor responsible for pancreatic development,
including b cell maturation and duodenal differentiation. b cell-
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selective disruption of Pdx1 in mice leads to the development of
diabetes,16 and mutations in PDX1 can cause a monogenic form
of diabetes (MODY4) in humans.17 In addition, PDX1 plays a ma-
jor role in maintaining b cell function and identity.18,19 Interest-
ingly, longitudinal analyses of metabolic parameters in T1D pa-
tients identified b cell dysfunction 5 years before diagnosis.20
Moreover, PDX1mRNA expression is decreased in coxsackievi-
rus B type 4 (CVB4)-infected human pancreatic samples.11,21,22
However, the molecular mechanisms of PDX1 alterations in dia-
betes linked to CVB4 infection remain elusive.
The molecular co-chaperone unconventional prefoldin RPB5
interactor (URI) is a nutrient- and stress-sensing protein main-
taining cellular homeostasis.23–25 URI controls the activity of
the b-linked N-acetylglucosamine (O-GlcNAc) transferase
OGT to regulate protein O-GlcNAcylation, conferring survival
mechanisms.26 In this regard, increased protein O-GlcNAcyla-
tion is directly linked to insulin resistance and hyperglycemia-
induced glucose toxicity.27 In addition, URI expression in hepa-
tocytes induces diabetes and non-alcoholic steatohepatitis.28
URI expression reportedly binds and sequesters in the cyto-
plasm the aryl hydrocarbon (AhR)- and estrogen receptor
(ER), inhibiting their nuclear transcriptional activity, causing
NAD+ depletion and liver cancer.29 Interestingly, cytoplasmic
ER is linked to better glucose homeostasis by maintaining b
cell survival in mice.30 Moreover, gender-specific differences
in glucose homeostasis reveal that sex hormones may play a
role in the development of diabetes.31 Recent data also suggest
that ER gene polymorphism affects the age of onset of T1D.32
Whether URI plays a role in b cell identity and diabetes still
needs to be determined.
Here, we demonstrate that CVB4 infection in human islets en-
grafted into mice and a rat insulinoma cell line causes the down-
regulation of URI and PDX1, affecting b cell function and identity.
Uri1flox/flox; Pdx1-cre mice, with pancreatic URI ablation, show
PDX1 loss in b cells and recapitulate clinical diabetes features.
Interestingly, pre-diabetic PDX1 heterozygous mice overex-
pressing URI in b cells are more glucose tolerant. Mechanisti-
cally, we show that URI depletion triggers ER nuclear transloca-
tion, leading to DNA methyltransferase 1 (DNMT1) expression
and causing Pdx1 promoter hypermethylation and silencing.
Treating Uri1flox/flox; Pdx1-cremice with the demethylating agent
procainamide reinstates PDX1 expression and protects against
diabetes. Finally, the b cells of human T1D and T2D patients
show URI, PDX1, and DNMT1 expression patterns similar to
those observed with CVB4 infection. Overall, our findings delin-
eate an unappreciated circuit in which CVB4 infection can lead to
diabetes through URI loss, causing Pdx1 silencing by DNMT1-
induced hypermethylation.
RESULTS
CVB4 Infection Causes URI Loss and Affects b Cell
Function and Identity
CVB4 exhibits selective tropism toward the pancreas, particu-
larly b cells in humans, which express its receptor.33 Neither
CVB3 nor CVB4 infection of C57BL/6 mouse islets consistently
results in diabetes, and the efficiency of the replication of these
viruses seems to be controversial and context dependent in
mice.34 We therefore used human islets infected with CVB4
and engrafted in immunodeficient mice11 in the experiments
reported here. At time of death, CVB4-infected mice presented
hypoinsulinemia and low C-peptide levels, and >40% had
developed hyperglycemia11 (Figures S1A and S1B; Table S1).
The quantification of insulin and glucagon immunofluorescent
cells in non-infected and CVB4-infected human grafts showed
that the proportion of insulin-producing cells significantly
decreased in infected samples and the proportion of glucagon-
producing cells increased (Figures 1A–1C), despite no significant
differences in the signal intensity of insulin and glucagon, as
shown by immunofluorescence (IF) (Figures S1C and S1D).
This suggests the loss of b cell identity and the conversion of b
cells to glucagon-producing a cells,35 a phenomenon that is
associated with PDX1 depletion.18 Thus, PDX1 is critical for b
cell maintenance and insulin production.18 As reported for the
loss of b cell identity, immunohistochemistry (IHC) analyses
showed that the percentage of PDX1+ cells was significantly
lower in virally infected human grafts than in non-infected sam-
ples (Figures 1D, 1E, and S1E).
Interestingly, URI expression was downregulated in CVB4-in-
fected samples compared to non-infected samples (Figures 1F
and 1G). Next, we analyzed human primary islets infected (or
not) with CVB4 ex vivo.11 Western blot (WB) revealed that
CVB4 infection caused the downregulation of PDX1 and URI at
48 h post-infection (Figure 1H). IF analysis demonstrated that
Figure 1. CVB4 Infection Causes URI Loss and Affects b Cell Function and Identity
(A) Immunofluorescence (IF) of insulin and glucagon from human islet xenografts in CVB4- or mock-infected mice.
(B and C) Quantification of the proportion of insulin (B)- and glucagon (C)-positive cells. At least 100 cells in the pancreatic grafts were counted per field, with up to
5 fields per sample (n = 10 and 7).
(D) Immunohistochemistry (IHC) of PDX1 from CVB4-infected human islet xenografts in mice. The dotted outlines represent the limit between the kidney and the
human graft.
(E) Quantification of PDX1+ cells (n = 10 and 7).
(F) IHC of URI from CVB4- or mock-infected human islet xenografts in mice.
(G) Quantification of URI staining intensity (n = 10 and 7).
(H) Western blot (WB) of URI, PDX1, and vinculin in CVB4- or mock-infected primary human islets (representative blot from 2 donors).
(I) IF of viral protein 1 (VP1) and PDX1 in INS-1E cells infected with CVB4 (or inactivated CVB4). Asterisk denotes CVB4-infected cells.
(J) Quantification of PDX1+ INS-1E cells infected with CVB4 or inactivated CVB4. At least 100 cells per field and 3 fields per samples were counted (N = 3).
(K) Quantification of PDX1 nuclear-positive cells from VP1+ cells (VP1) and VP1 cells (NO VP1) in CVB4-infected INS-1E cells. At least 100 cells per field and 3
fields per sample were counted (N = 3).
(L) WB of URI, PDX1, caspase-3, and vinculin in INS-1 cells infected with CVB4 (MOI 5, 0.5, 0.05, and 0.005) or inactivated CVB.
Data are means ± SEMs. Statistical analysis done using Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bars, 50 mm in (D) and (F); 25 mm in (A) and (I).




the number of PDX1+ cells was decreased, although the percent-
age of glucagon-positive cells remained unchanged (Figures
S1F–S1H). Since human primary islets are a relevant source of
material but at the same time limited in amount and manipula-
bility, we decided to pursue our investigations in the INS-1E
and INS-1 rat insulinoma cell lines.36 Notably, INS-1E cells are
a clonal cell line of INS-1 with higher insulin sensitivity. IF in
INS-1E cells confirmed that CVB4 particles decreased the total
number of PDX1 cells 48 h post-infection when compared to
cells infected with inactivated viruses, whereas none of the in-
fected cells were PDX1+ (Figures 1I–1K). Moreover, WB analysis
indicated that URI and PDX1were dose-dependently downregu-
lated in CVB4-infected INS-1E and INS-1 cells, without any
remarkable signs of viral cytotoxic effects (no cell death was de-
tected) (Figures 1L and S1I–S1K). Notably, CVB4 expression
was detected by staining viral protein 1 (VP1), a component of
the coxsackievirus family found in human T1D samples, and
the antibody specificity of which was previously character-
ized.37,38 Interestingly, human URI overexpression in CVB4-in-
fected INS-1 cells showednuclear PDX1expression (FigureS1L).
These data indicate that CVB4 infection causes URI and PDX1
downregulation, possibly affecting b cell identity and function, in-
dependent of viral cytotoxicity. Thus, URI loss may be a CVB4-
mediated trigger of disease and participate in the ‘‘viral para-
digm’’ of diabetes.
Genetic URI Ablation in Mouse Pancreas Leads to
Glucose Intolerance and Premature Death
To further explore the consequences of URI loss in the pancreas,
we generated a genetic model of URI ablation in murine
pancreas by crossing Uri1 floxed mice with transgenic mice
expressing Cre recombinase under control of the Pdx1 pro-
moter, which is induced during embryonic development
(E8.5),39 obtaining Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (Fig-
ure S2A). IHC and WB analyses indicated that URI was specif-
ically downregulated in the pancreases of Uri1flox/flox; Pdx1-cre
mice, but not in their other organs (Figures S2B–S2D). Crossing
URI Uri1flox/flox; Pdx1-cre with the reporter line R26-stop-
enhanced yellow fluorescent protein (EYFP)40 confirmed the
specific expression of EYFP, and consequently, the absence of
URI-expressing cells in the pancreatic islets, as shown by
EYFP+ signals by IHC (Figures S2E and S2F).
Uri1flox/flox; Pdx1-cremice had reduced survival, dying quickly
after adulthood. Notably, 50% of males died within 15 weeks of
birth, whereas females died later (Figures 2A and S2G). At
7 weeks of age, Uri1flox/flox; Pdx1-cre males displayed reduced
pancreas weights, hyperglycemia, and hyperinsulinemia at fast-
ing (Figures 2B–2D). In addition, glucose intolerance was de-
tected in Uri1flox/flox; Pdx1-cre males and females after 6 h of
fasting (Figures 2E and S2H) and insulin secretion was reduced
in Uri1flox/flox; Pdx1-cre mice when compared to their control lit-
termates (Figure 2F). No significant differences in insulin sensi-
tivity were detected between Uri1flox/flox; Pdx1-cremales and fe-
males (Figures S2I and S2J), and total amounts of pancreatic
insulin were lower inUri1flox/flox; Pdx1-cremice than in control lit-
termates (Figure 2G). Furthermore, b cell density was higher (Fig-
ures 2H and 2I), but b cell mass and average pancreatic islet size
were significantly lower (Figures 2J and 2K) in Uri1flox/flox; Pdx1-
cre mice than in littermate controls, even though Ki67 and
cleaved caspase 3 staining, respectively, indicated that prolifer-
ation and apoptosis were not affected in Uri1flox/flox; Pdx1-cre
mice (Figures S2K and S2L), corroborating the non-cytotoxic ef-
fects shownwith CVB4 infections11 (Figures S1L–S1K). Thus,Ur-
i1flox/flox; Pdx1-cre mice present a drastic b cell compartment
alteration, with features resembling an idiopathic T1D or a
MODY-like diabetes, highly reminiscent of MODY4 (Figure 2L).
URI Controls PDX1 Expression and b Cell Identity in
Mice
We next analyzed the expression of PDX1 following URI deple-
tion. Since the Uri1flox/flox; Pdx1-cre phenotype was more pro-
nounced in males than in females, we focused the following
study on male mice. WB analysis revealed that PDX1 expression
was significantly decreased in the pancreases of Uri1flox/flox;
Pdx1-cremice, but not in their littermate controls, while IF stain-
ing in pancreatic islets showed the downregulation of PDX1 in b
cells (Figures 3A and S3A–S3C). Quantitative reverse transcrip-
tase-PCR (qRT-PCR) analyses of pancreatic samples indicated
that PDX1 target genes Ins-1 and Ins-2 were downregulated in
Uri1flox/flox; Pdx1-cre mice (Figure 3B), confirming that PDX1
expression is altered in Uri1flox/flox; Pdx1-cre pancreases. In
addition, we observed the downregulation of Pdx1 gene expres-
sion in INS-1E cells after URI downregulation using specific small
interfering RNA (siRNA) against URI (siURI) (Figure S3D).
Notably, WB analysis of the duodenum indicated that the
expression of PDX1 was halved in Uri1flox/flox; Pdx1-cre mice
but no differences were detected in intestinal architecture and
permeability (Figures S3E–S3G). Moreover, PDX1 was not ex-
pressed in the ileum as shown by WB (Figure S3E). Therefore,
the effects seen in Uri1flox/flox; Pdx1-cre mice may be caused
by URI-mediated PDX1 regulation in the pancreatic islets.
The above results suggest that the effects observed inUri1flox/
flox; Pdx1-cre mice may be caused by the loss of pancreatic
PDX1. Since PDX1 is crucial for the development and mainte-
nance of pancreatic lineages, the b cell compartment in Uri1-
flox/flox; Pdx1-cre mice may not have developed and matured
properly, resulting in the inadequate production of insulin and
control of glycemia. We therefore analyzed pancreases of 2-
day-old Uri1flox/flox; Pdx1-cre mice. IF analysis showed that
they had reduced PDX1 and insulin levels (Figures 3C–3F). More-
over, like 7-week-old Uri1flox/flox; Pdx1-cremice, 2-day-old mice
had significantly smaller pancreatic islets (with lower organoso-
matic indices) and higher blood glucose levels than littermate
controls (Figures 3G–3I). At this stage, Uri1flox/flox; Pdx1-cre
mice did not show any deviations in b cell density (Figure S3H),
suggesting that alterations in the endocrine compartment are still
to come. Thus, URI deletion may affect pancreas homeostasis
via PDX1 downregulation.
Notably, blood glucagon levels were significantly increased in
7-week old Uri1flox/flox; Pdx1-cre mice, while their a cell identity
was maintained, according to qRT-PCR analyses of Glucagon
and Arx-1 (Figures 3J and S3I), despite the dramatic loss of the
endocrine compartment observed in Uri1flox/flox; Pdx1-cre
mice. Forcing PDX1 expression can also convert a small propor-
tion of a cells into b cells.41. In addition, the endogenous reprog-
ramming of a cells into b cells, induced by viral gene therapy that




Figure 2. Genetic URI Ablation in Mouse Pancreas Leads to Glucose Intolerance and Premature Death
(A) Survival curve of Pdx1-cre and Uri1flox/flox; Pdx1-cre males (n = 10 and 7).
(B) Organosomatic index of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (n = 9 and 6).
(C) Fasting glucose levels of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre males (n = 10 and 7).
(D) Fasting plasma insulin levels in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 8 and 5).
(E and F) Glucose tolerance and insulin secretion tests in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 10 and 7).
(G) Pancreatic insulin levels in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 12 and 4).
(legend continued on next page)




reinstates PDX1 expression, can reportedly reverse autoimmune
diabetes in both b cell-toxin-induced diabetic mice and autoim-
mune non-obese diabetic (NOD) mice, a unique animal model of
T1D.42 Moreover, following experimental b cell ablation, a and
d cells can be converted into insulin-producing cells acquiring
b cell properties.43–46 More important, recent findings suggest
that CVB4 infection of human primary pancreatic ductal cell cul-
tures impairs differentiation into insulin-producing cells.47 We
therefore checked for the presence of polyhormonal cells
(secreting glucagon and insulin), a phenomenon partly mediated
by the loss of PDX1.43 Significantly, confocal images of Uri1flox/
flox; Pdx1-cre pancreatic islets showed increased polyhormonal
cells (Figures 3K and 3L).
Next, we investigated whether CVB4 infection could be
directly responsible for the loss of b cell identity and the transdif-
ferentiation into insulin-glucagon bihormonal cells.48 Confocal
co-IF of insulin and glucagon revealed the presence of bihormo-
nal cells in CVB4-infected human islet grafts (Figures 3M and
3N), suggesting that viral infection induces the reprogramming
of hormonal cells.35 In addition, we did triple staining for insulin,
glucagon, and VP1.8,9 Results demonstrated that b cell-specific
tropism of CVB4 viruses favored bihormonal cell apparition (Fig-
ures S3J and S3K). Strikingly, we could not observe any infected
cells expressing nuclear PDX1—only some remaining cyto-
plasmic expression (Figure S3K). Moreover, gene expression
analysis in CVB4-infected human primary islets indicated that
b cell (INS, NKX6-1, and PDX1) transcripts were downregulated
and a cell (ARX and GCG)-specific markers were upregulated
(Figure S3L). These data indicate that CVB4 causes URI downre-
gulation, affecting b cell identity and function, possibly through
PDX1 loss.
URI Is Required to Maintain Glucose Homeostasis by
Regulating PDX1 Expression
We have surmised that URI is required to maintain glycemia in
conditions in which b cell functions are altered. Accordingly,
we generated a knockin mouse (designated hURI1(+/KI);
Pdx1(tTA/+)) expressing FLAG-tagged human URI (hURI1) via a
tetracycline-dependent transactivator (tTA(OFF)) that has re-
placed the coding region of the endogenous Pdx1 gene to
ensure correct temporal and spatial expression of the regulat-
able transactivator (tTA(OFF): Pdx1(tTA/+) mouse) (Figure S4A).49
In the absence of doxycycline, hURI1(+/KI); Pdx1(tTA/+) mice ex-
pressed hURI specifically in b cells from a single allele from em-
bryonic development (Figures S4B–S4D). More important,
hURI1(+/+); Pdx1(tTA/+) littermates lacked hURI expression and
displayed a pre-diabetic phenotype, likely due to the disruption
of one Pdx1 allele and reduced PDX1 levels.49 IF analysis
showed that hURI1(+/KI); Pdx1(tTA/+) mice had higher PDX1
expression than littermate controls with only the Pdx1(tTA/+) allele
(Figures 4A–4C). In addition, hURI-expressing Pdx1-tTA mice
(hURI1(+/KI); Pdx1(tTA/+) mice) displayed better glucose clearance
than the pre-diabetic hURI1(+/+); Pdx1(tTA/+)mice (Figures 4D and
S4E), although hURI1(+/KI); Pdx1(tTA/+) mice displayed the same
fasting or post-prandial glucose levels and similar fasting insulin
levels (Figures S4F and S4G). hURI1(+/KI); Pdx1(tTA/+) mice had
better insulin secretion, but no differences in insulin sensitivity
between them, and the pre-diabeticmicewere detected (Figures
4E, S4H, and S4I). IF and transmission electron microscopy
(TEM) analyses of b cells, respectively, indicated that insulin
levels and numbers of insulin secretion granules were signifi-
cantly increased in hURI1(+/KI); Pdx1(tTA/+) mice (Figures 4F–
4H). Notably, no changes in their b and a cell densities were
observed, but b cell mass and proliferation were also enhanced;
apoptosis was not observed in hURI1(+/KI); Pdx1(tTA/+)mice, how-
ever (Figures S4J–S4N). Consistent with increased insulin con-
tent, insulin secretion tests in isolated islets of hURI1(+/KI);
Pdx1(tTA/+)mice showed increased secretion after 30min of stim-
ulation by glucose, potassium chloride (KCl), tolbutamide, or for-
skoline (Figure 4I). Crosses of Uri1flox/flox; Pdx1-cre and hURI1(+/
KI); Pdx1(tTA/+)mice had better glucose clearance thanUri1flox/flox;
Pdx1-cre and hURI1(+/+); Pdx1(tTA/+) mice (Figure 4J). hURI1(+/KI);
Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre mice also had normal survival
parameters, while hURI1(+/+); Pdx1(tTA/+) ; Uri1flox/flox; Pdx1-cre
controls died before birth (Figure 4K), indicating that URI is
required to maintain glucose homeostasis by regulating PDX1
expression.
Next, to check the effect of URI deletion at adult stages, we
genetically ablated URI in adult stages by maintaining hURI1(+/
KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre mice without doxycycline
to activate hURI expression until 8 weeks of age. Then, mice
were treated with doxycycline for 4 weeks to stop hURI induc-
tion. Notably, hURI1(+/KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre mice
with hURI repression did not show any signs of diabetes (Figures
S2O and S2P). Thus, early URI ablation in the pancreas is dele-
terious for pre- and post-natal development, supporting the fact
that URI loss in mice may lead to a MODY-like diabetes.
URI Controls Pdx1 Methylation via ERa-Activating
DNMT1
We next studied Pdx1 promoter regulation by URI in cell lines
in vitro. HEK293T cells were transiently transfected with different
Pdx1 promoter constructs fused to a gene encoding the enzyme
chloramphenicol acetyltransferase (CAT).50. Notably, HEK293T
cells are readily transfectable and represent a more convenient
model with high PDX1 mRNA levels (Human Protein Atlas). The
constructs contained the distal promoter, including the highly
conserved AI, AII, and AIII regions homologous to human
PDX1 promoter regions PH1, PH2, and PH351; the proximal pro-
moter region to the transcription start site; and/or different 30 re-
gions of the promoter (Figure S5A).52 AII and AIII regions are
known to contain regulatory sequences for b cell-specific lineage
expression and function. HEK293T cells were then transfected
with either siURI to deplete URI expression or pCDNA3-HA-
(H) Hematoxylin and eosin staining (H&E) of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice.
(I–K) b cell density (I), b cell mass (J), and average pancreatic islet size (K) of Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreatic islets (n = 8 and 5).
(L) Comparison and characteristics of diabetes in human and Uri1flox/flox; Pdx1-cre mouse.
Data aremeans ±SEMs. Statistical analysis done usingMantel-Cox test, Student’s t test, and 2-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar, 100 mm
in (H).




Figure 3. URI Controls PDX1 Expression and b Cell Identity in Mice
(A) WB of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases, normalized to GLUT2 expression.
(B) qRT-PCR of indicated mRNA from 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases, normalized to b-actin mRNA expression (n = 6 and 5).
(C) IF of insulin and PXD1 in 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (post-natal).
(D–F) Quantification of PDX1 nuclear expression (D), percentage of PDX1+ cells (E), and insulin expression (F) in 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre
pancreases (n = 6 and 7).
(G) Pancreas to body weight of 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 5).
(legend continued on next page)




URI to overexpress HA-URI (Figure S5B). Analysis of CAT activity
48 h post-transfection showed that URI downregulation signifi-
cantly reduced Pdx1 promoter activity, encompassing the regu-
latory elements AI–AIII, whereas URI overexpression increased it
(Figures S5C and S5D). Thus, URI may regulate the core func-
tions of pancreatic development and b cells through the Pdx1
promoter.
Decreased PDX1 expression has been correlated with
increased Pdx1 promoter methylation in the glucose intrauterine
growth retardation model in rats.53 We therefore analyzed the
methylation status of the Pdx1 promoter at three sites containing
the regulatory elements AI–AIII, supposedly regulated by URI.
Bisulfite analysis and quantification of CpG-methylated sites in
Uri1flox/flox; Pdx1-cre pancreases indicated global methylation
of the Pdx1 promoter, with a most stringent increase in the reg-
ulatory element A2 (Figure 5A and S5E–S5H), suggesting that
URI loss increases Pdx1 methylation, possibly leading to its
silencing in b cells and diabetes.
DNMT1, an S-adenosylmethionine-dependent DNA methyl-
transferase catalyzing DNA methylation, was recently proposed
to maintain b cell identity; thus, its expression may be critical in
the pathogenesis of diabetes, possibly through regulation of
the Pdx1 promoter.43 Pdx1 methylation is decreased in
DNMT1 heterozygous mice.54 Interestingly, in the pancreases
ofUri1flox/flox; Pdx1-cremice, DNMT1was significantly increased
and specifically enriched in b cells, as shown by qRT-PCR and
IHC (Figures 5B–5F). Notably, analyses of Trdmt1, Dnmt3a,
and Dnmt3b transcript levels indicated that there were no
changes in the expression of other DNA methyltransferases in
Uri1flox/flox; Pdx1-cre pancreases (Figure S5I).
ERa is a well-known transcription factor that induces DNMT1
expression by binding to its promoter.55 In addition, ERa report-
edly forms an inactive cytoplasmic complex with URI and
HSP90, and URI deletion promotes the nuclear translocation
that ERa requires for transcriptional activity.29 We detected
endogenous interaction between URI and ERa in INS-1E cells,
MCF-7 breast cancer cells (known to have high levels of
ERa56) and Pdx1-cre pancreases in co-immunoprecipitation
(coIP) experiments, but not in Uri1flox/flox; Pdx1-cre pancreases
(Figures 5G, S5J, and S5K), indicating its specificity. As
mentioned, translocation to the nucleus is required for the tran-
scriptional activity of ERa, and URI has been shown to sequester
it in the cytoplasm.29 By subcellular fractionation of INS-1E cells,
we confirmed that URI knockdown induced ERa nuclear translo-
cation and PDX1 downregulation (Figure 5H). We then verified
that ERa directly activates Dnmt1 expression, by chromatin
immunoprecipitation (ChIP) assays, and showed that ERa bound
to Dnmt1 promoter regions containing two ER elements (EREs)
(Figures 5I and S5L).57 Notably, URI could not be found to bind
Pdx1 promoter (Figure S5M). Therefore, URI binds and seques-
ters ERa in the cytoplasm, thereby abolishing the transcription of
DNMT1. URI loss increases DNMT1 expression and Pdx1 pro-
moter methylation.
Procainamide-Mediated DNMT1 Inhibition Reinstates
PDX1 Expression and Glucose Tolerance by Reducing
Hypermethylation of Pdx1 Promoter in Mice
Prompted by these observations, we treated Uri1flox/flox; Pdx1-
cre mice since conception with the demethylating agent procai-
namide, a highly specific non-nucleoside inhibitor of DNMT1.58
Procainamide-treated Uri1flox/flox; Pdx1-cre mice showed better
glucose clearance than non-treated Uri1flox/flox; Pdx1-cre mice
(Figure 6A). Furthermore, we detected no aberrations in their in-
sulin tolerance (Figure S6A). IF, WB, and qRT-PCR analyses
showed that the lost PDX1 expression was reinstated in pancre-
atic islets of procainamide-treated Pdx1-cre and Uri1flox/flox;
Pdx1-cre mice (Figures 6B–6F). Pdx1 promoter hypermethyla-
tion was reversed in procainamide-treated Uri1flox/flox; Pdx1-
cre mice when compared to non-treated Uri1flox/flox; Pdx1-cre
mice (Figures 6G, S6B, and S6C). Interestingly, pancreatic
PDX1 and URI were substantially increased in procainamide-
treated Pdx1-cremice, and the expression patterns were similar
(Figure 6E), suggesting homeostatic methylation of Uri1 pro-
moter to balance URI expression. In line with these findings, in-
sulin content in procainamide-treated Uri1flox/flox; Pdx1-cre was
slightly lower (but not significant) when compared to procaina-
mide-treated Pdx1-cremice (Figure S6D), most likely due to dif-
ferences in URI expression in procainamide-treated mice (Fig-
ure 6E). Notably, pancreatic AhR expression was not altered in
procainamide-treated mice when compared to non-treated
mice (Figure S6E).
Finally, the analysis of CVB4-infected human grafts showed a
significant increase in the number of DNMT1+ cells, inversely
correlating with URI loss (Figures 6H and 6I). Thus, URI loss ac-
tivates ERa-mediated DNMT1 expression in pancreases,
possibly by promoting Pdx1 promoter methylation and silencing,
and diabetes.
URI and PDX1 Expression Correlates in Diabetic Mice
PDX1 is known to be downregulated in mouse pancreases by
nutrient-induced stress factors, such as a high-fat diet (HFD),59
further highlighting the possible contribution of nutrient overload
in diabetes pathogenesis. We therefore treated C57BL/6J mice
with HFD for 32 weeks and found, concomitant to PDX1 and in-
sulin downregulation, a significant decrease in URI expression in
the endocrine compartment (Figures S7A and S7B). PDX1 loss
may also putatively account for b cell failure in HFD-induced
T2D.60 Accordingly, HFD-treated hURI1(+/KI); Pdx1(tTA/+) mice
(H) Area of pancreatic islets per field in 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (n = 6 and 7).
(I) Fasting glucose levels of 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 7 and 8).
(J) Fasting glucagon levels of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre mice (n = 12 and 11).
(K) Confocal IF of insulin (red) and glucagon (green) in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases.
(L) Quantification of polyhormonal cells per field in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases. Up to 5 fields in 1 cut per sample were examined
(n = 5 and 6).
(M) Confocal IF of insulin and glucagon from CVB4-infected human pancreas xenografts in mice. Asterisks represent bihormonal cells.
(N) Quantification of bihormonal—insulin and glucagon—positive cells. Up to 5 fields in 1 cut per sample were examined (n = 10 and 7).
Data are means ± SEMs. Statistical analysis done using Student’s t test. *p < 0.05; **p < 0.01. Scale bar, 25 mm in (C) and 50 mm in (K) and (M).
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presented better glucose tolerancewith no apparent alteration in
insulin sensitivity (Figures S7C and S7D). In addition, crosses of
hURI1(+/KI); Pdx1(tTA/+) and heterozygous leptin-deficient mice
(ob/+) (ob/+; hURI1(+/KI); Pdx1(tTA/+) mice) had better glucose
tolerance, resembling hURI1(+/+); Pdx1(tTA/+)mice, than glucose-
intolerant ob/+ mice (ob/+; hURI1(+/KI); Pdx1(tTA/+) ) (Figures
S7E and S7F). These findings suggest that URI overexpression
protects from nutrient overload-induced diabetes (possibly
mediated by PDX1 loss). They also suggest a general mecha-
nism involving the activation of Pdx1 promoter methylation and
silencing in response to various exogenous stimuli implicated
in the pathogenesis of diabetes in humans.
Coxsackieviruses and URI, DNMT1, and PDX1
Expression Correlate in Human Diabetic and Non-
diabetic Patients
Next, to investigate the clinical relevance of our findings, we
analyzed coxsackievirus VP1 and URI, insulin, PDX1, and
DNMT1 levels in pancreases from non-diabetic (n = 54), T2D
(n = 19), and T1D (n = 6) patients. T2D patients suffer from
compensative b cell expansion, hyperinsulinemia, and b cell fail-
ure in an insulin resistance state,61 whereas the loss of b cell
identity is found in T1D patients.43,46 In this context, b cell density
was not changed in diabetic samples when compared to non-
diabetic samples, but b cell mass was decreased (Figures S7G
and S7H). Notably, IF analysis showed that URI and insulin
expression in the islets was decreased in T2D and T1D human
samples (Figures 7A–7C and S7I). URI positively correlated
with insulin levels (Figure 7D). Moreover, analysis of PDX1 and
DNMT1 expression in the islets by IHC indicated that percentage
of PDX1+ cells decreased in T2D and T1D patients when
compared to the non-diabetic samples, whereas DNMT1+ cells
significantly increased (Figures 7E–7G). Strikingly, URI and
PDX1 expressions positively correlated (Figures 7H and S7J).
Next, we investigated the presence of VP1 in T2D and T1D
samples since coxsackievirus infection correlates with a higher
risk of T1D incidence,11,62 and VP1 has been detected in some
pancreatic islets of T2D patients and all samples of a cohort of
patients with recent onset of T1D.14,63 An IHC analysis of VP1
staining revealed 83% positive samples (5 of 6) in the endocrine
pancreas of T1D patients and 23% positive samples (5 of 22) in
T2D samples, in contrast to only 5% positive samples (3 of 57) in
non-diabetic samples (Figure 7I). Finally, we analyzed the per-
centage of PDX1+ and DNMT1+ cells and we scored for URI
expression in endocrine pancreases from VP1+ samples.
PDX1, DNMT1, and URI expression correlated with the infection
status (Figures 7J–7L), corroborating results shown in b cell lines
and in human grafts. These data suggest a strong correlation be-
tween CVB4 infection, URI loss, DNMT1 expression, and PDX1
silencing, thereby causing diabetes.
DISCUSSION
The dense networks of interactions between environmental
stressors and biological systems pose major challenges in ef-
forts to elucidate the underlying mechanisms of diabetes and
obtain the holistic understanding required for robust prevention
and treatment. Responses to environmental factors through
the regulation and expression of proteins that have important
protective functions, but are potentially damaging if inappropri-
ately expressed, may play frequently underestimated roles in
various pathological states. Here, we provide mechanisms gov-
erning the relationship between enterovirus infection and the
development of diabetes. We show that CVB4 infection causes
URI loss in b cells, leading to DNMT1 expression and PDX1
silencing, and subsequently inducing b cell loss and hyperglyce-
mia. Thus, URI and DNMT1 expressions and PDX1 silencing
causally link enterovirus infection to diabetes.
Although enterovirus infection has been mainly linked to T1D,
our present work supports that CVB4 infection can induce a loss
of b cell identity, leading to hyperglycemia in the absence of
autoimmunity. This loss of PDX1 suggests a MODY-like dia-
betes, reminiscent of MODY4, caused by loss-of-function muta-
tions in PDX1,17 rather than T1D. This is also supported by the
fact that the phenotype observed in Uri1flox/flox; Pdx1-cre mice
is strongly dependent on the restoration of PDX1 expression.
Moreover, that early URI ablation in the pancreas is deleterious
to pre- and post-natal development supports the evidence that
URI loss in mice may lead to a MODY-like diabetes, although
an idiopathic T1D subtype cannot be excluded.
T1D has long been considered a genetic autoimmune disease
in which T cell infiltration induces the destruction of insulin-pro-
ducing b cells of pancreatic islets. However, more recent data
implicate environmental assaults as premises of b cell dysfunc-
tion and T1D onset.20 In this context, viral-mediated b cell iden-
tity loss and transdifferentiation are novel, but also controversial
lines of investigation.48 In fact, T1D is related to the presence of
islet cells dually expressing insulin and glucagon; likewise,
Figure 4. URI Is Required to Maintain Glucose Homeostasis by Regulating PDX1 Expression
(A) IF of PDX1 and insulin in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+) pancreases.
(B and C) Quantification of PDX1 nuclear expression (B) and percentage of PDX1+ cells (C) in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+)
pancreases (n = 8 and 7).
(D and E) Glucose tolerance (D) and insulin secretion tests (E) in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+) females (n = 7 and 6).
(F) IF of insulin and glucagon and transmission electron microscopy in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+) pancreases.
(G) Quantification of insulin in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+) pancreases (n = 5).
(H) Quantification of insulin granules in 7-week-old hURI1(+/KI); Pdx1(tTA/+) and hURI1(+/+); Pdx1(tTA/+) pancreases (n = 4).
(I) Insulin secretion in isolated islets of 7-week-old hURI1(+/+); Pdx1(tTA/+) and hURI1(+/KI); Pdx1(tTA/+) pancreases stimulated for 30 min with either 2.6 nM glucose,
18 nM glucose, 20 mM KCl, 100 mM tolbutamide, or 1 mM forskolin (n = 12 and 11).
(J) Glucose tolerance test in 7-week-old Pdx1-cre, hURI1(+/+); Pdx1(tTA/+),Uri1flox/flox; Pdx1-cre, and hURI1(+/KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre females (n = 5, 5,
8, 10). Statistical analysis done between hURI1(+/+); Pdx1(tTA/+) and hURI1(+/KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre.
(K) Statistical differences in natality of hURI1(+/+); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre and hURI1(+/KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre mice.
Data are means ± SEMs. Statistical analysis done using Student’s t test and 2-way ANOVA. *p < 0.05; **p < 0.01. Scale bar, 2 mm in (F) and 25 mm in (A) and (F).




chemically induced models of T1D promote b cell transdifferen-
tiation.64,65 Among the possible environmental risk factors for
T1D, enterovirus infections are considered to be the most argu-
ably evidenced. Similar to our own results, Krogvold et al.14 de-
tected in all of the pancreatic islets of patients with new-onset
T1D the presence of a few enterovirus positive cells. In particular,
CVB4 has been linked to increased T1D incidence.66 In line with
this, our data suggest that in a dose-dependent manner, CVB4
infection leads to b cell failure via the loss of URI, which increases
methylation and silencing of the Pdx1 promoter through ERa--
mediated DNMT1 expression. Dotta et al.9 observed changes
in neither insulin content nor the proportion of b cells in isolated
islets from early-onset CVB4-infected T1D samples, although in-
sulin secretion was decreased. This suggests that b cell function
was affected independently of b cell failure and cytotoxic effects
of CVB4. Therefore, it would be interesting to check the b cell
identity and URI levels in the T1D cohort published by Dotta
et al. using cutting-edge techniques9,67,68 or conduct experi-
ments ex vivo by infecting live pancreas slices from human organ
donors with CVB4.69 Such a study could elucidate the mecha-
nisms of diabetes pathogenesis by enteroviruses by providing
direct functional data in intact human pancreas tissues.
b cell dysfunction has been considered a major consequence
of and explanation for virally induced T1D, without matching the
long-term onset of T1D. For this reason, non-cytolytic effects
must take place and have been underestimated by others. In
Figure 5. URI Controls Pdx1 Methylation via ERa-Activating DNMT1
(A) Percentage of methylation in 3 different sites of Pdx1 promoter in Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (n = 6 and 7).
(B) IHC of DNMT1 in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases. Dashed lines denote endocrine compartment.
(C) Quantification of nuclear and cytoplasmic DNMT1 in endocrine and exocrine compartment of 7-week-old URIpdx1 pancreases (n = 5).
(D) qRT-PCR of Dnmt1 in Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (n = 6 and 5).
(E) IHC of DNMT1 and insulin in 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases.
(F) Quantification of DNMT1+ cells in 2-day-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases (n = 5 and 6).
(G) Co-immunoprecipitation (coIP) of URI and ERa in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases.
(H) WB of cytoplasmic and nuclear fractions of INS-1E cells transfected by either siURI or siCtl.
(I) Chromatin immunoprecipitation (ChIP) in MCF7 cells using anti-ER antibody and 3 different sets of primers of the Dnmt1 promoter.
Data are means ± SEMs. Statistical analysis done using Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar, 50 mm in (B) and (E).
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this regard, we have shown that CVB4 in a dose-dependent
manner causes the loss of URI without provoking any cytotoxic
effects or cell death, even at high doses of CVB4. Finally, the
CVB4 sequence generated by Dotta et al. shared >99% nucleo-
tide identity with the CVB4 strain sequenced by Sickles et al. in
1951, raising questions on the CVB4 origin from Dotta
et al.9,70,71 Therefore, environmental factors may drive the devel-
opment of an idiopathic T1D, but the immune components, as a
secondary response, could contribute to b cell failure.
This observation is also supportedby ourwork conducted using
human samples that shows that long-term b cell alteration due to
viral infection may participate in the onset of both T1D and T2D,
although an idiopathic T1D subtype could not be excluded either.
It is indeed relevant to observe that the incidence of VP1 detection
may be greater in T1D than in T2D patients. It is thus tempting to
speculate that CVB4 can lead to heterogenic, and in some cases,
fulminant autoimmune responses in T1D that could obliviate URI-
mediated PDX1 downregulation and b cell identity loss. Alter-
ations in Pdx1 methylation status may also be induced by a
broader spectrumof factors that can impair glucose homeostasis,
such as nutrient overload,59 corroborating its importance to the
maintenance of proper b cell function during various environ-
mental assaults. Although lineage tracing experiments would be
needed to demonstrate cellular plasticity in diabetes in Uri1flox/
flox; Pdx1-cremice, our data suggest that the conversion of b cells
into a cells may contribute to the loss of b cells,46,72 and the re-
programming of a cells into insulin-producing cells may be an
adaptive mechanism that compensates for the destruction of b
cells during diabetes pathogenesis.
Finding the ideal model in mice for the study of b cell homeo-
stasis remains challenging. The Pdx1-driven transgenic mouse
model is a useful tool to study the endocrine pancreas, but it
also may target other PDX1-expressing cells, including the duo-
denum. Although hyperglycemia has been shown to induce in-
testinal barrier dysfunction, dysbiosis, and enhanced abdominal
cavity in amodel of streptozotocin (STZ) administration,73 we did
not observe defects in intestinal structure and permeability.
Notably, the specific deletion of PDX1 in intestinal epithelial cells
did not lead to a specific phenotype, related to neither glucose
homeostasis nor epithelial barrier disruption.74 Therefore, alter-
ations in the intestinal epithelium may not be the cause of
glucose intolerance or the increased morbidity in the Uri1flox/
flox; Pdx1-cre mice. The cause of Uri1flox/flox; Pdx1-cre mouse
death may be related to hyperglycemia, as mice collected at a
humane endpoint were displaying blood glucose levels
>500 mg/dL (data not shown).
Uri1flox/flox; Pdx1-cre mice showed increased glucose intoler-
ance and higher mortality in males. Female mice are more insulin
sensitive when compared to males, and glucose levels settled
back to normoglycemia after 60 min in females, whereas males
were still hyperglycemic (Figures 2E and S2H). Since the cyto-
plasmic ER maintains b cell survival and glucose homeostasis
and ER gene polymorphism affects the age of onset of
T1D,30,32 it is tempting to speculate that estrogen levels may pro-
vide protective effects in diabetes. Interestingly, URI binds and
inhibits ER, limiting the estrogen effects. Knowing that males
have less estrogen than females, the ER inhibition by URI may
be more pronounced in males, explaining the gender differences
observed in Uri1flox/flox; Pdx1-cre mice.
We also note that b cell reprogramming to alternative islet cell
fates may putatively account for b cell failure in obesity-induced
diabetes.3,75–77 As URI is downregulated following nutrient sur-
pluses, potentially leading to diabetes, and it is a molecular
chaperone that responds to various environmental stressors,
its loss may be a key pathogenic trigger of diabetes and feature
of the ‘‘environmental/pathogen paradigm’’ of disease. How URI
expression is regulated by various environmental stressors re-
mains an open question. CVB4 and nutrient overload can be in-
flammatory, and hence, inflammatory cues may modulate URI
expression in the pancreas.
Finally, since severe acute respiratory virus-coronavirus-2
(SARS-CoV-2) may trigger diabetes by damaging b cells inde-
pendently of the immune response,78–80 it would be interesting
to check whether SARS-CoV-2 downregulates URI in b cells
and induces PDX1 silencing and hence the development of
‘‘new-onset diabetes.’’79
The identification of URI and DNMT1 expression and PDX1
silencing as likely causal links between environmental stresses
and diabetes may facilitate the development of innovative new
avenues and mechanism-based therapeutics to counter the dis-
ease. Targeting hypermethylation of the Pdx1 promoter using
DNA methyltransferase inhibitors with antiviral therapies may
therefore be future elegant preventive strategies for patients at
high risk of developing diabetes. Notably, despite their limita-
tions as to their off-target effects and efficient delivery, several
DNA demethylases are licensed for clinical use in cancer ther-
apy, which should aid the development of such strategies.
Limitations of Study
We acknowledge that the mechanism described in this article
may represent one of many disease endotypes that are most
likely related to an idiopathic T1D or MODY-like diabetes—
Figure 6. Procainamide-Mediated DNMT1 Inhibition Reinstates PDX1 Expression and Glucose Tolerance by Reducing Hypermethylation of
Pdx1 Promoter in Mice
(A) Glucose tolerance test in Pdx1-cre and Uri1flox/flox; Pdx1-cre males treated or not treated with procainamide (n = 6 and 5).
(B) IF of 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases treated or not treated with procainamide and stained for insulin and PXD1.
(C and D) Quantification of nuclear PDX1 expression (C) and percentage of positive cells (D) in 7-week-old Pdx1-cre andUri1flox/flox; Pdx1-cre pancreases treated
or not treated with procainamide (n = 5, 6, 6, and 7).
(E) WB of URI, PDX1, and vinculin in 7-week-old Pdx1-cre and Uri1flox/flox; Pdx1-cre pancreases treated or not treated with procainamide.
(F) qRT-PCR of Pdx1 in Uri1flox/flox; Pdx1-cre males treated or not treated with procainamide (n = 6).
(G) Percentage of methylation in 2 different sites of Pdx1 promotor in Uri1flox/flox; Pdx1-cre males treated or not treated with procainamide (n = 5 and 4).
(H) IHC of DNMT1 in CVB4-infected human pancreas xenografts in mice. Dashed lines denote endocrine compartment.
(I) Quantification of DNMT1+ cells (n = 5 and 6).
Data are means ± SEMs. Statistical analysis done using Student’s t test and 2-way ANOVA. *p < 0.05. Scale bar, 50 mm in (B) and (H).




(legend on next page)




possibly to MODY4—and further validation in human tissues
would be required. In particular, we did not attempt to infect
mice with CVB4 and assess for URI, DNMT1, and PDX1 expres-
sion and the development of diabetes. In addition, the CVB4
infection of live pancreas slices from human organ donors69
would have validated our mechanistic data and would have
been a proof-of-concept study in vivo, linking functional data
to intact human tissues.We used the Pdx1-Cre line to genetically
ablate URI in pancreata, although the Rip-Cre line could have
also been tested. However, neither the Pdx1-Cre line nor the
Rip-Cre line deletes specifically in b cells, and both lines may
present advantages and disadvantages. Rip-Cre line has strong
unspecific effects in the hypothalamus. Experimental evidence
suggests that Rip-Cre mice display glucose intolerance.81 The
Ins1-CreERT2 line could have been an alternative, particularly
to deplete URI in the adult stage. Furthermore, mouse lineage
tracing experiments would have supported the transdifferentia-
tion of b cells into a cells. Finally, a population-based epidemio-
logical study with cancer patients treated with DNAmethyltrans-
ferase inhibitors could demonstrate their potential clinical
benefits for diabetes.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Alexa Fluor 488 Goat anti-Chicken IgY (H+L) Life Technologies A-11039; RRID:AB_2534096
Alexa Fluor 488 Goat anti-Mouse IgG Life Technologies A-11001; RRID:AB_2534069
Alexa Fluor 488 Donkey anti-Mouse IgG Life Technologies A-21202; RRID:AB_141607
Alexa Fluor 555 Goat anti-Mouse IgG Life Technologies A-21422; RRID:AB_2535844
Alexa Fluor 555 Goat anti-Rabbit IgG Life Technologies A-21429; RRID:AB_2535850
Alexa Fluor 555 Donkey anti-Goat IgG Life Technologies A-21432; RRID:AB_2535853
Alexa Fluor 647 Goat anti-Rabbit IgG (H+L) Life Technologies A-21245; RRID:AB_2535813
Alexa Fluor 647 Donkey anti-Rabbit IgG Life Technologies A-31573; RRID:AB_2536183
Goat Polyclonal anti-Mouse HRP conjugated Dako P0447; RRID:AB_2617137
Goat Polyclonal anti-Mouse AP conjugated Sigma-Aldrich A0168; RRID:AB_257867
Goat Polyclonal anti-Rabbit HRP conjugated Dako P0448; RRID:AB_2617138
Goat polyclonal anti-PDX1 R&D Systems AF2419; RRID:AB_355257
Mouse BD Fc block BD BioSciences 553141; RRID:AB_394656
Mouse monoclonal anti-ERa Santa Cruz Biotechnology Sc-8002; RRID:AB_627558
Mouse monoclonal anti-Glucagon Sigma-Aldrich G2654; RRID:AB_259852
Mouse monoclonal anti-HA Tag (16B12) BioLegend MMS-101R; RRID:AB_291262
Mouse monoclonal anti-PDX1 R&D Systems MAB2419; RRID:AB_2268098
Mouse monoclonal anti-URI This paper N/A
Mouse monoclonal anti-Vinculin Sigma V9131; RRID:AB_477629
Mouse monoclonal anti-VP1 Dako M7064; RRID:AB_2118128
Rabbit polyclonal anti-Caspase 3 Cell Signaling Technology 9662; RRID:AB_331439
Rabbit monoclonal anti-GST Sigma G7781; RRID:AB_259965
Rabbit monoclonal anti-HSP90 Cell Signaling Technology 4877; RRID:AB_2233307
Rabbit monoclonal anti-Ki67 (SP6) Master Diagnostica MAD-000310QD
Rabbit polyclonal anti-URI This paper N/A
Rabbit polyclonal anti-Chromogranin A Abcam ab15160; RRID:AB_301704
Rabbit polyclonal anti-DNMT1 Santa Cruz Biotechnology sc-20701; RRID:AB_2293064
Rabbit polyclonal anti-Glut2 Novus Biologicals NBP2-22218; RRID:AB_2335858
Rabbit polyclonal anti-Insulin Cell Signaling Technology 4590; RRID:AB_659820
Bacterial and Virus Strains
CVB4 JVB ATCC VR-184#
Biological Samples
Human diabetic pancreatic samples CNIO Biobank, Biobanc-Mur, MarBiobank,
Vasque Biobank, Andalusian Public Health
System Biobank, and Biobank of IDIBAPS.
N/A
Human primary islets Prodo Laboratories, Inc 11
Chemicals, Peptides, and Recombinant Proteins
2-mercaptoethanol Sigma Aldrich M3148
2-Propanol 99,7% Panreac Quimica 11610901214
30%(w/v) Acrylamide: 0.8% /9w/v) Bis-Acrylamide
Stock Solution (37.5:1)
ProtoGel EC-890
Acetic Acid Fisher Scientific 100063.1000
Agarose Electrophoresis Grade Apollo Scientific BIA1176
Aprotinin Sigma Aldrich A1153
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Aqua Live Dead Life Technologies L34957
Blotting-Grade Blocker BioRad 170-6404
BD Cytofix BD BioSciences 51-2090KZ
BD Perm/Wash BD BioSciences 51-2091KZ
Bovine Serum Albumin Sigma Aldrich A7906
Bradford Protein Assay BioRad 5000001
Bromophenol Blue Sigma Aldrich B0126
Citric Acid 500 g Sigma Aldrich C0759
Chloroform Sigma Aldrich C2432
Collagenase P Roche 11213857001
Coomassie Brilliant Blue BioRad 161-0436
CompleteTM, EDTA-free Protease Inhibitor Cocktail Roche COEDTAF-RO
D-Glucose 250 g Sigma Aldrich G7528
DAPI 4.6-diamidino-2-phenylindole 5 mg Sigma Aldrich D9542
DMEM Life Technologies, S.A. 31885-049
DMSO Sigma Aldrich D8418
DNase I recombinant, RNase-free Roche 04716728001
Doxycycline 1g Sigma Aldrich D9891
DTT (Dithiothreitol) Sigma Aldrich D9779
EcoRI Digestion Enzyme New England Biolabs R0101S
EcoRV Digestion Enzyme New England Biolabs R3195M
EDTA (Ethylenediaminetetraacetic acid) Sigma Aldrich ED
EGTA (Ethylene glycol-bis(2aminoethylether)-N, N, N,
N-tetraacetic acid
Sigma Aldrich E3889
Ethanol 96% Panreac Quimica 141085.1214
Fetal Bovine Serum Sigma Aldrich F7524-500ML
FITC/Dextran Sigma Aldrich 46945
Formalin solution 10% Panreac Quimica S.L.U. HT501128
Forskolin Sigma Aldrich F6886
Glutamax Supplement 200mM GIBCO Life Technologies, S.A. 35050-038
Gluthathione Sepharose 4 Fast Flow GE Healthcare 17-5132-01
Glycerol Sigma Aldrich G5516
Hematoxylin Panreac Quimica, S.L.U. 2552981610
HEPES Life Technologies, S.A. 15630-049
Hydrogen Peroxide Solution 500 ml Sigma Aldrich H1009
LB Agar /20 Plates (Free antibiotics) Laboratorios Conda, S.A. 10354
Liquid DAB + Substrate Chromogen System Dako K3468
Luminol (97%) Sigma Aldrich 123072
Magnesium Chloride (MgCl2) Sigma Aldrich 208337
NaCl (Sodium Chloride) Sigma Aldrich S9625
NP-40 Alternative Calbiochem D00120899
p-Coumaric Acid Sigma Aldrich C9008
Paraformaldehyde Electron Microscopy Sciences 19202
PBS 10X (For IHC/IF) ALAOS PB515M-10
PBS w/o Ca2+/ Mg2+ (For tissue culture) Cultek S.L.U. BE-17516F
Penicillin-Streptomycin 100ML GIBCO Life Technologies, S.A. 15070-063
PMSF (Phenlmethylsufonyl Fluoride) Sigma Aldrich P7626
Propidium iodide Sigma Aldrich P4170
Potassium Chloride Sigma Aldrich P9541
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Procainamide hydrochloride, 99% Fischer Scientific 10167743
Protein A Sepharose 4 Fast Flow GE Healthcare 17-1279-01
Protein G Sepharose 4 Fast Flow GE Healthcare 17-0618-01
Proteinase K VWR Internacional Eurolab, S.L. 0706-100 mg
Prolong Gold Antifade Reagent 10 ml Life Technologies P36930
Resazurin Sodium Salt Sigma Aldrich R7017
Rnase A solution Sigma Aldrich R6148
SDS (Sodium dodecyl sulfate) BioRad 1610302
Sodium Citrate Tribasic Dihydrate Sigma Aldrich S4641
Sodium Deoxycholate Sigma Aldrich D6750
Sodium Fluoride Sigma Aldrich S7920
Sodium Orthovanadate Sigma Aldrich S6508
Sodium Phosphate Dibasic Sigma Aldrich S3264
Sodium Pyrophosphate Tetrabasic Sigma Aldrich S6422
Sunflower seed oil from Helianthus annus Sigma Aldrich 88921-1L-F
TAE 50X (Tris-Acetic Acid-EDTA) ALAOS TA475M
Tolbutamide Sigma Aldrich T0891
Triton X-100 Sigma Aldrich T8787
Trizma Base Sigma Aldrich T1503
Tween 20 Sigma Aldrich P7949
Critical Commercial Assays
AmpONE TM Taq DNA polymerase GeneAll 501-050
Avidin/ Biotin Blocking Kit Vector Laboratories SP-2001
Bradford Protein Assay Kit Bio-Rad 5000006
Catalase Activity Assay Kit Abcam ab83464
Dako Fluorescence Mounting Medium DAKO S3023
FuGENE HD Transfection Reagent Promega E2311
GenEluteTM HP Plasmid Midiprep Sigma Aldrich NA0200S
GoTaq qPCR Master Mix Promega A6002
In Situ Cell Death Detection Kit, Fluorescein Roche 11684795910
Lipofectamine 2000 Transfection Reagent Thermo Fisher 11668019
Lipofectamine RNAiMAX Transfection Reagent Thermo Fisher 13778100
M-MLV Reverse Transcriptase Life Technologies 28025013
Mouse on Mouse (M.O.M.) Basic Kit Vector Laboratories BMK-2202
Prime-It II Random Primer Labeling Kit Agilent Technologies 300385
QIAquick Gel Extraction Kit QIAGEN 28704
QIAquick PCR Purification Kit QIAGEN 28104
SIGMAFAST Fast Red TR/Naphthol AS-MX Sigma Aldrich F4648
SuperScript VILO cDNA Synthesis Kit and Master Mix Life Technologies 11754050
TNT T7 Coupled Reticulocyte Lysate System Promega L1170
TSA TM Plus Biotin Kit PerkinElmer NEL749A001KT
Ultrasensitive Mouse Insulin ELISA Mercodia 10-1249-01
Glucagon EIA kit Sigma Aldrich RAB0202-1KT
Vectastain ABC HRP Kit (Peroxidase, Goat IgG) Vector Laboratories PK-4005
Vectastain ABC HRP Kit (Peroxidase, Mouse IgG) Vector Laboratories PK-4002
Vectastain ABC HRP Kit (Peroxidase, Rabbit IgG) Vector Laboratories PK-4001
Vectastain ABC HRP Kit (Peroxidase, Rat IgG) Vector Laboratories PK-4004
(Continued on next page)





REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Cell Lines
293T cells (HEK) ATCC CRL-3216
MCF7 cells ATCC HTB-22TM
INS-1E cells 36 N/A







Pdx1tTA mouse: 129X1/SvJ-Pdx1tm1Macd Spanish National Cancer
Research Centre (CNIO)
J:79206








Col1a1tm1(tetO-URI1)Ndj Spanish National Cancer
Research Centre (CNIO)
J:217463




Primers For ChIP, see Table S3 This Paper N/A
Primers For Bisufite Sequencing, see Table S4 This Paper N/A
Primers For Genotyping, see Table S5 This Paper N/A
Primers For qRT-PCR, see Table S5 This Paper N/A
ON-TARGETplus Non-Targeting Pool Dharmacon D-001810-10
ON-TARGETplus Human URI1 siRNA Dharmacon L-017399-00
siGLO green transfection indicator Dharmacon D-001630-01








pGEX-4T-1-URI (1-267) This Paper N/A
pGEX-4T-1-URI (1-534) This Paper N/A
pGEX-4T-1-URI (156-534) This Paper N/A
pGEX-4T-1-URI (1-517) This Paper N/A
pGEX-4T-1-URI (282-534) This Paper N/A
pGEX-4T-1-URI (390-534) This Paper N/A
pGEX-4T-1-URI (466-534) This Paper N/A
pGEX-4T-1-URI (156-283) This Paper N/A
pGEX-4T-1-URI (1-158) This Paper N/A
pcDNA3.1-hURI (1-534) This Paper N/A
pcDNA3.1-hURI (1-193) This Paper N/A
pcDNA3.1-hURI (194-389) This Paper N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Nabil
Djouder (ndjouder@cnio.es).
Materials Availability
Materials are available upon request to N.D. Mouse lines generated in the lab will be subjected to standard material transfer
agreements.
Data and Code Availability
This study did not generate any unique datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models
To engraft the islets NSG (NOD/Cg-Prkdcscid IL2rgtm1WJL Tg(Ins2-HBEGF)6832Ugfm/Sz) were used as previously described.11
To specifically express human URI (hURI1(+/KI)) in the pancreas, ColhURI (WT) mouse previously described29 was crossed with a
line containing the tetracycline-dependent transactivator (tTA) under the control of the Pdx1 promoter - i.e., Pdx1(tTA/+) mouse49 - to
generate hURI1(+/KI); Pdx1(tTA/+) mouse. Pancreatic-specific ectopic hURI1 expression was allowed since embryonic stage E8.5
when Pdx1 gene expression starts.
To induce URI deletion specifically in b cells, URI lox mouse previously described24 was crossed with a line containing the Cre
recombinase under the control of Pdx1 promoter - i.e, Tg(Pdx1-cre)6Tuv mouse39 - generating the Uri1flox/flox (also named as
Uri1+/+, as no phenotype was observed in this mice), Uri1flox/+; Pdx1-cre and Uri1flox/flox; Pdx1-cre mice, respectively
To re-induce URI expression in URI-deleted pancreas, Uri1flox/flox; Pdx1-cre mouse was crossed with the hURI1(+/KI); Pdx1(tTA/+)
mouse in order to generate the hURI1(+/KI); Pdx1(tTA/+); Uri1flox/flox; Pdx1-cre mouse.
To express EYFP in URI-deleted pancreas, Uri1flox/flox; Pdx1-cre mouse was crossed with the R26R-EYFP mouse,82 previously
reported and present in house in order to generate the Uri1flox/flox; Pdx1-cre; R26R-EYFP mouse.
To induce URI deletion specifically in b cells in adult mice, 8 to 10 weeks old hURI1(+/KI); Pdx1(tTA/+);Uri1flox/flox; Pdx1-cremice were
treated continuously with doxycycline diet.
hURI1(+/KI); Pdx1(tTA/+) mouse was crossed with ob/+ (B6.V-Lepob/J) mouse (Jackson lab)83 to generate the ob/+; hURI1(+/KI);
Pdx1(tTA/+) mouse. ob/+ mouse has been described to have glucose impaired response and hyperinsulinemia.84
Continued
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Precellys 24 Bead Mill homogenizer Bertin Technologies Equation 03119-200-RD000.0
Accu-Chek Aviva Glucometer Roche Diagnostics 200602
Accu-Chek Aviva Glucose strips Roche Diagnostics 6916678001
Amersham Protran 0.2 mm NC GE Healthcare 10600001
Chow diet - 18% fat, 58% carbohydrates, and 24%
proteins
Harlan Laboratories 2018S
Doxycycline Hyclate diet (200 mg/ Kg) Envigo TD.04104
High fat diet - 45% fat, 35% carbohydrates, and 20%
proteins
Research Diets D12451




CVB4-Infected Mice Grafted with Human Islets
Coxsackievirus (CVB4)-infected and non-infected human islets engrafted in NOD/Cg-Prkdcscid IL2rgtm1WJL Tg(Ins2-HBEGF)
6832Ugfm/Sz (NSG-Tg(RIP-DTR)) mouse paraffin samples were kindly provided by Jennifer Wang, MD, University of Massachusetts
Medical School (UMMS).11 In short, immunodeficient and diabetes-prone NSG mice with transgenic expression of the diphtheria
toxin receptor were treated with Diphtheria Toxin to induce hyperglycemia and loss of the murine b cell pool. Diabetic mice were
then engrafted in two experiments with 3000 human islets in each mouse from one single, distinct human donor in each experiment.
Human islet grafts are from two independent experiments (Exp 2 and Exp 3),11 and were originally obtained from the Integrated Islet
Distribution Program under protocols approved by the Institutional ReviewBoard of the University of MassachusettsMedical School.
These islets were transplanted in the mouse kidney in order to restore normoglycemia and were infected with CVB4. Briefly, mice
were intraperitoneally injected with normal saline solution (Mock) or 1 3 104 plaque-forming units (pfu) of CVB4 strain JVB. Param-
eters on body weights and, blood glucose and insulin and C peptide levels are reported in Table S1. Paraffin-embedded samples
from human islets were performed either at humane end point or end of the experiment (day 44 or day 49 for Exp 2 and Exp 3, respec-
tively). Samples for experiments 2 and 3 were pooled in order to obtain statistical significance. No obvious changes in serum C-pep-
tides, blood insulin levels, insulin mRNA expression or insulin/glucagon positive cell ratio in the mock samples were found between
both experiments.11
Human Islets for the Experiments In Vitro
Human primary islets were kindly provided by Jennifer Wang, MD, University of Massachusetts Medical School (UMMS) as
described. In short, primary human islets from adult donors without diabeteswere obtained fromProdo Laboratories, Inc. (Aliso Viejo,
CA). Donor #17092 is a 44-year-oldmale African American with a BMI of 31 and a 4.7%glycated hemoglobin (HbA1c). Donor # 18200
is a 61-year-old female from a non-documented race with a BMI of 28.9 and a 5.6% glycated hemoglobin (HbA1c).
Human Pancreatic Samples
Human diabetic pancreatic samples and data were obtained from the CNIO Biobank thanks to the help of Maria-Jesus Artiga and
from Biobanc-Mur, MarBiobank, Vasque Biobank and Andalusian Public Health System Biobank, integrated in the Spanish Biobank
Network and funded by Instituto de Salud Carlos III. We are also thankful to the Biobank of IDIBAPS, Barcelona, to provide samples to
Dr. Anna Novials. Samples were processed following standard operating procedures with the appropriate approval of the Ethics and
Scientific Committees. Males and females were included in the study as indicated. Additional details on donors are provided in Table
S2.
Cell Lines
INS-1, INS-1E, MCF-7 and HEK293T cells were maintained in high-glucose DMEM supplemented with glutamine, 10% (MCF-7 and
HEK293T cells) or 15% (INS-1E cells) fetal bovine serum (FBS) and 100 units/ml penicillin and 0.1 mg/ml streptomycin. Cells were




All mice were housed in pathogen-free conditions. No inclusion criteria were used. The mice were housed with a 12-hour light/dark
cycle between 8:00 and 20:00 in a temperature-controlled room (22 ± 1C) . All experiments were approved by the CNIO-ISCIII Ethics
Committee and Community of Madrid (CAM) and performed in accordance with the guidelines for ethical conduct in the care and use
of animals as stated in the international guiding principles for biomedical research involving animals, developed by the Council for
International Organizations of Medical Sciences. Littermates were always used as controls. Males and females were respectively
used for the study. Age/developmental stage of mice is included appropriately in the text and Figure Legends. Food (Harlan Labo-
ratories and Research Diets Inc.) and water were provided ad libitum, unless described elsewhere.
Mouse Diets and Treatments
Mice were fed either with chow diet (18% fat, 58% carbohydrates, and 24% proteins) (Harlan Laboratories, 2018S), doxycycline hy-
clate diet (200 mg/ Kg) (TD.04104, ENVIGO) at concentration of 50 mg/kg or high-fat-diet (HFD) (45% fat, 35% carbohydrates, and
20% proteins) (Research Diets, D12451).
Procainamide (ARCOS, 10167743) was purchased from Fisher Scientific S.L. and stored under manufacturer’s conditions. Procai-
namide was dissolved in water at the concentration of 0,32 g/kg and used as oral treatment to breeding pairs and weaned mice. The
solution was changed every second day, freshly prepared and filtered.
Isolation of Mouse Pancreatic Islets
Mice pancreatic islets were obtained by Treatment by Collagenase P of Bile duct cannulated pancreases followed by density
gradient with Histopaque 1100 as described previously.85 In short, bile duct cannulated mice were injected with collagenase-P




(1,4mg/ml) in G solution (0.35 g NaHCO3/L, 0.35 g NaHCO3/L in HBSS) up to 5 mL to inflate all pancreatic lobes and placed into
15 mL centrifuge tube on ice. Pancreases were then incubated in a water bath at 37C for 10 minutes and hand-shaken hard for 5 s
and placed back on ice, filled up to 15 mL of G solution to slow digestive process. Digested pancreases were washed twice by
centrifugation for 5 minutes at 300 g at room temperature, discarding supernatant and adding 10 mL of G solution. Pancreases
were then passed through 100 um strainers into 50 mL centrifuge tubes, and added additional 10 mL of G solution. Supernatant
were discarded. Pellets were resuspended in 10 mL Histopaque 1100 solution and 10 mL of G solution was added with precaution
so as to not disrupt Histopaque – G solution phases. Pancreas were the centrifuged at 900 g for 20 minutes at room temperature
with no brake setting. After centrifugation islets at the interphase are collected and transferred to a new tube and 25 mL of G so-
lution is added.
Tubes are washed by flushing with G solution and centrifuged at 450 g for 4 minutes at room temperature. Another round of wash-
ings is done by adding 10 mL of G solution and centrifugation at 450 g for 4 minutes at room temperature. Finally, pellets were re-
suspended with Culture solution (RPMI 1640, 10% fetal calf serum, penicillin (100 U/mL)/streptomycin (100 mg/mL).
Insulin Secretion Test (IST) in Isolated Islets
10 Pancreatic isolated islets per condition were hand-picked and pre-incubated in 1 mL Krebs–Ringer bicarbonate buffer supple-
mented with 2.8 mmol l1 glucose and 0.5% BSA at 37C in an atmosphere of 5% CO2%–95% O2 for 1 hour. Islets were then
glucose stimulated by 16.7 mmol l1 glucose or not and in the presence or absence of different activators of insulin secretion
for 30 minutes. Islets were then harvested and pelleted by centrifugation. Supernatants were taken for insulin release
quantification.
Glucose Tolerance Test (GTT) in Mice
Mice were fasted for 6 hours and weighed. Blood glucose levels were determined doing a distal cut in the tail and placing a drop of
blood in a test strip of a glucometer (ACCU-Check). A solution of 2 g of glucose/kg of body mass as administered by intraperitoneal
(IP) injection. Blood glucose levels were measured at 0, 15, 30, 60 and 90 min in all cases and 120 min and 150 min in HFD-treated
mice.
Insulin Tolerance Test (ITT) in Mice
Mice were fasted for 6 hours and weighed. Blood glucose levels were determined doing a distal cut in the tail and placing a drop of
blood in a test strip of a glucometer (ACCU-Check). A solution of 0.75 U of IU/g of body mass as administered by intraperitoneal (IP)
injection. Blood glucose levels were measured at 0, 15, 30, 60 and 90 min in all cases and 120 min in HFD-treated mice.
Insulin Secretion Test (IST) in Mice
Blood samples collected from the submandibular vein at 0 and 30minutes respectively before and after intraperitoneal injection of 2 g
of glucose/kg of bodymass, placed in heparin tube and centrifuged 15min at 3000 g. 25 mL of plasmawere utilized tomeasure insulin
levels using an enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, 10-1249-01) for mouse insulin.
Plasmid Transfection and siRNA Experiments
URI overexpression experiments in INS-1, INS-1E and HEK293T cells were performed using pcDNA3-HA-URI and pcDNA3-HA as
control.26 Plasmids were transfected using FuGENE 6 in HEK293T cells and using Lipofectamine2000 in INS-1 and INS-1E cells, ac-
cording to the manufacturer’s instructions. Cells were analyzed 48-hour post-transfection.
Knockdown experiments in HEK293T cells were performed using ON-TARGET plus SMART pool siRNA targeting human URI (L-
017399-00) as well as control siRNA (D-001810-10-20), purchased from Dharmacon. siRNAs were transfected using Lipofectamine-
RNAiMAX (Life technologies, S.A., 13778) according to the manufacturer’s instructions.
URI in INS-1 and INS-1E cells was knock-down using three different small interfering RNA (siRNA) againstUri1 sequence (Origene,
SR502040) and Lipofectamine2000 transfectant (Life technologies, 11668): Cells were plated at 70% confluence at transfection in
24-well plates. siRNAs 20 mM and Lipofectamine2000 were diluted in Opti-MEM transfection media (Life technologies), mixed for
and incubated for 20min and then applied to the cells on day of seeding and 24h onward. siGLO green transfection indicator (Thermo
Scientific Dharmacon, D-001630-01-05) and was added as qualitative control of siRNA delivery to the nucleus. Cells were analyzed
48-hour post-transfection.
CVB4 Infections in Cells
HumanCoxsackievirus B4 JVB strain was purchased from the American TypeCulture Collection (ATCCVR-184#), was propagated in
HEK293T cells and culture supernatants containing the viruses kept at80C. Non-infecting-CVB4 particles were prepared by incu-
bating in 56C water bath during 30 minutes.
Monolayers of INS-1 and INS- 1E cultures set up in 24-well dishes with glass coverslips or in 6-well dishes were infected with CVB4
at MOI ranging from 50 to 0,001. Cells were collected after 24h incubation.




CVB4 Infection of Human Islets
150 to 200 human primary islets were cultured with CMRL-1066 media (Thermo Fisher Scientific) supplemented with 10% fetal
bovine serum, l-glutamine, and penicillin/streptomycin and infectedwith 13 106 plaque-forming units of CVB4/100 islets by following
previously reported procedures.22 Mock-infected islets were treated with media alone.
Flow Cytometry
Cell were trypsinized and 106 cells were harvested and washed in PBS two times. After final wash, cells were incubated in 70%
ethanol overnight at 4C. After washing twice in PBS, cells were incubated in 0.5 mL PBS containing 10 mg/ml RNase A, 50 mg/ml
propidium iodide and 0,1 Triton x100 overnight in the dark at 4C.
Pancreatic Insulin Content
Between a quarter to a half of pancreatic tail was placed in 5 mL of acid ethanol (1.5% HCl in 70% ethanol) overnight at 20C. The
day after, tissue was homogenized with a Precellys 24 tissue homogenizer (15 s x 2 power set to 5500 w) and incubated overnight at
20C. Thereafter, samples were spun down at 2000 rpm for 15 min at 4C. Supernatant was transferred to new tubes and stored at
20C. 100 mL of acid ethanol extract were neutralized with 100 mL of Tris pH 7.5. Neutralized solution was diluted 1:500. Insulin con-
tent of samples wasmeasured by enzyme-linked immunosorbent assay (ELISA) kit (Mercodia, 10-1249-01), followingmanufacturer’s
instructions. Analysis was donewith Gene 5 software. Total protein content per sample was quantifiedwith Bradford protein assay kit
(Bio-Rad, 5000006) and bovine serum albumin (BSA) as standard protein. Optical density of samples and BSA was measured at
562nm using Gene 5 program.
Blood Parameters
Blood was collected from the heart of sacrificedmice and transferred to EDTA containing tubes for hemogram analysis using Abacus
Junior Vet analyzer (Diatron, UM-AJV-01-276). Plasma was collected after 4000 rpm, 20 minutes at 4C centrifugation and kept at
80C until further analysis. Insulin and glucagon were measured by using kits as indicated in the KEY RESOURCES TABLE.
FITC-Dextran Assay
For FITC/Dextran permeability assay mice were first starved for 12 hr and then given 60 mg/100 g of body weight of FITC/Dextran
(46945, Sigma) dissolved in water by oral gavage as previously described.24 Serumwas collected 4 hr later and analyzed by Synergy
HTXMulti-ModeMicroplate Reader (BioTek) at the 485 nm excitation wavelength and 528 nm emission wavelength by using Gen5TM
software (BioTek).
Immunoprecipitation
For immunoprecipitation of endogenous URI and estrogen receptor a (ERa), freshly harvested pancreases, MCF-7 or INS-1E cells
were lysed in the following buffer (50 mM Tris-HCl pH.8, 100 nM NaCl, 1% NP-40, PMSF 50 mg/ml, 2 mM EDTA and 5% glycerol),
supplemented with protease inhibitors. Immunoprecipitation was performed using 20 mL Protein A and/or G-Sepharose beads. Cell
lysates were pre-cleared for 1 hour at 4C using beads in absence of antibodies. Supernatant was then collected for input (whole cell
extract, WCE) and for incubation with antibody at 4C for 2 hours and then transferred to Protein A and/or G beads for additional 1
hour. Beads with bound proteins were washed 4 times in 1 mL immunoprecipitation buffer prior elution in 40 mL 2x Laemmli buffer.
Chromatin Immunoprecipitation
For chromatin immunoprecipitation (ChIP) assay, MCF-7 cells were cross-linked for 10 min at RT in 1% formaldehyde. Cross-linking
reactions were stopped by adding 1.25 M glycine to a final concentration of 125 mM. Cells were centrifuged for 10 min at 4C and
then washed in cold PBS. Cells were lysed with 1 mL of lysis buffer-1 (50 mMHEPES-KOH, pH 7.5, 140 mMNaCl, 1 mM EDTA, 10%
glycerol, 0.5% NP-40, 0.25% Triton X-100, 1 X protease inhibitor) followed by centrifugation at 4C and resuspension of the pellet in
lysis buffer-2 (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1 X protease inhibitors. Finally, the pellets were
resuspended in 1 mL of lysis buffer-3 (10 mM Tris-HCl, pH8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM N-lauroylsarcosine, 1 X protease
inhibitors), and 100 mL of 10% Triton X-100 were added and sonicated for 20 min in a Covaris sonicator. The soluble fraction was
quantified with Bradford, and 400 mgwas used to immunoprecipitate the transcription factors and IgG’s used as a control. Chromatin
and antibodymixtures were incubated overnight at 4C in total volume of 500 ml. Immunoprecipitated mixture was washed with a low
salt buffer (20 mM Tris-HCl, pH 8.0, 150 mMNaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100), followed by high salt buffer (20 mM
Tris-HCl, pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100) and finally with LiCl wash buffer (10 mM Tris-HCl,
pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% Na-Deoxycholate and 1% NP-40). Samples were decross-linked by resuspending the beads
in 210 mL of elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA and 1% SDS), incubating at 65C for 15 min and treating with 2.5 ul
(from 32 mg/mL) of RNase A for 2 hours. Next, 4 mL of (20 mg/ml of stock) of Proteinase K was added and incubated at 55C for 2
hours. DNA was extracted by phenol/chloroform/isoamylalcohol mixtures, washed with 80% EtOH and resuspended in 200 mL of TE
buffer. This was followed by qRT-PCR. The specific primers used are listed below in Table S3.





6.106 INS-1E cells were lysed in 160 mL Buffer C (10 mM HEPES pH 7.6, 3 mMMg Cl2, 40 mM KCl, 5% Glycerol, 0.5% NP-40, 2mM
DTT, 0.1 mg/ml PMSF 10 mg/ml Aprotinin and 1X Protein inhibitor cocktail), vortexed 10 s, incubated 5min at 4C and checked under
microscope. Subcellular fractionation were performed as previously described.86 The resulting supernatant was saved and the pellet
was washed with 120 mL Buffer C. Both supernatants were combined and used as the cytoplasmic fraction for subsequent exper-
iments. Pellet was washed another time with Buffer C and supernatant was discarded. Pellet was resuspended with 120 mL Buffer N
(10 mM HEPES-NaOH pH 7.9, 0.1 mM EDTA, 0.1 mM EGTA, 1.5 mM MgCl2, 420 mM NaCl, 25% Glycerol, 0.5 mM DTT, 0.5 mM
PMSF and 1X Protein Inhibitor Cocktail (Roche, 04693116001). The lysate was vortexed for 10 s, placed for 10 min at 4C and pel-
leted. Supernatant was used as nuclear fraction.
CAT Assay
Catalase activity in HEK293T cells was measured by the Catalase Activity Assay Kit (Abcam, ab83464) following manufacturer’s in-
structions. Briefly, the catalase reacts with H2O2 to produce water and oxygen. The unconverted H2O2 reacts with probe to produce a
product that can be measured colorimetrically at OD 570 nm.
Immunoblotting
Immunoblotting was performed from isolated cells, INS-1, INS-1E cells, HET293T cells, and different mouse organs i.e., spleen, kid-
ney, colon, skin, ovaries, hypothalamus, heart and pancreas. Pancreas was removed from mice and pancreatic tail was directly
frozen in liquid nitrogen. Tissues or cells were lysed in RIPA lysis buffer (10 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mMNaF, 20 mMNa4P2O7, 2 mMNa3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10% glycerol and sup-
plementedwith 10mg/ml proteases inhibitor aprotinin and 1mMPMSF) and tissues were lysed by homogenization using Precellys 24
BeadMill homogenizer (Bertin Technologies) (15 s x 2 power set to 5500w) and then clarified by centrifugation at 4Cand 10.000 g for
10 min. Protein concentration was measured by using the Bradford protein assay kit from Bio-Rad and BSA as standard protein.
1 mg/ml concentrated lysates were made by boiling the appropriate amount of protein lysates with 5X Laemmli buffer (10% SDS,
50% glycerol, 0.004% bromophenol blue in 0.2 M Tris-HCL of pH 7) and 0.1M Dithiothreitol (DTT) at 95C, for 2 min. 10-30 mg of
protein lysates were subjected into SDS-PAGE gels, and transferred to nitrocellulose membranes. The membranes were blocked
with 5% nonfat milk in Tris-buffered saline containing 1% Tween 20 for 1h at room temperature. Blots were immune-stained with
indicated antibodies. Immunoblots were processed by ECL (2.5 mM Luminol, 0.4mM p-Coumaric Acid and Tris-HCl 0.1M, pH 8.5
for Luminol Solution and 0.02% hydrogen peroxide and Tris-HCl 0.1M, pH 8.5 for H202 solution; mixed 1 in 1 before revelation).
Immunohistochemistry
Pancreas was prepared by disposing the head of the pancreas on smoking paper and fixing it with 10% formalin along with the rest of
the organs in paraffin cassettes. Samples were incubated overnight in formalin at room temperature and processed for paraffin
embedding. Sections of 3 mm were de-paraffinized, rehydrated and antigen retrieved by using 0.1 M sodium citrate buffer (pH
6.5). After blocking endogenous peroxidase using 3% H2O2 (in water) for 10 minutes, sections were then blocked with 1:200
goat serum in PBS/0.2%Triton for 1 hour at room temperature. Furthermore, sectionswere incubatedwith primary antibodies diluted
in PBS/0.2% Triton overnight at 4C. Slides were washed twice in PBS and Vectastain ABC kit (PK-4001 for rabbit; PK-4002 for
mouse; PK-4005 for goat) was used for secondary antibody. Sections were washed twice in PBS and incubated with 33-diamino-
benzidinetetracloride (DAB) (Dako, K346811). For double staining, anti-Mouse IgG (whole molecule)-alkaline phosphatase antibody
produced in goat (A3562, Sigma-Aldrich) and SIGMAFAST Fast Red TR/Naphthol AS-MX kit were used (F4648, Sigma-Aldrich).
Counterstaining was performed with hematoxylin.
Immunofluorescence
For immunofluorescence, sections were directly blocked after deparaffinization and antigen retrieval with 1:200 goat serum and 5%
BSA in PBS/0.2% Triton for 1 hour at room temperature. Incubation with primary antibodies in PBS/0.2% Triton was performed over-
night at 4C. After several washings in PBS, slides were incubated with Alexa488/555/647 conjugated secondary antibodies for 1
hour at room temperature, followed by DAPI (1 mg/ml) staining. Mounting was done with fluorescent mounting media (DAKO,
S3023). Quantification was performed either by counting the number of positive cells in a minimum of six 10X or 20X microscopic
fields, the percentage of positive area or the mean fluorescence intensity of ROI using NIS-Elements AR.
Electron Microscopy
Samples were fixed with 2% v/v glutaraldehyde in 0.05M sodium phosphate buffer (pH 7.2). Following isolation of suitable specimen
blocks, the samples were rinsed three times in 0.15M sodiumphosphate buffer (pH 7.2) and subsequently post-fixed in 1%w/vOsO4
in 0.12 M sodium phosphate buffer (pH 7.2) for 2-hour. The specimens were dehydrated in graded series of ethanol, transferred to
propylene oxide and embedded in Epon according to standard procedures. Sections, approximately 60 nm thick, were cut with a
Ultracut 7 ultramicrotome (Leica, Vienna, Austria) and collected on copper grids with Formvar supporting membranes (Ted Pella,
01700-F) stained with uranyl acetate (Agar scientific, AGR1260A) and lead citrate (Agar scientific, AGR1210), and subsequently
examined with a Philips CM 100 Transmission EM (Philips, Eindhoven, the Netherlands), operated at an accelerating voltage of




80 kV and equipped with an OSIS Veleta digital slow scan 2k x 2k CCD camera. Digital images were recorded with the ITEM software
package. Electron microscopy was performed by Klaus Qvortrup, Professor, MD, PhD, University of Copenhagen Faculty of Health
and Medical Sciences, CFIM, Copenhagen, Danmark.
Bisulfite Sequencing
Unmethylated cytosines of DNA samples were converted to uracils by treating DNAwith the EpiTect Bisulfite kit (QIAGEN, 59104), as
recommended by themanufacturer. Fragments corresponding to Site 1 to 3 were amplified by PCRwith Platinum Taq DNA Polymer-
ase (Invitrogen, 10342020) and an annealing temperature of 60C. Primer sequences are listed in Table S4. PCR products were
cleaned up on NucleoFast PCR plates (Macherey-Nagel, 743100.10) and cloned on pGemT-easy (Promega, A1360). Plasmid col-
onies from each sample were sequenced and analyzed with BiQ Analyzer software as reported.87
Genotyping
For genotyping, finger DNA was extracted by overnight incubation of fingers with 500 mL of the cell lysis buffer (1% SDS, 0.1 M NaCl,
0.1 M EDTA, 0.05 M Tris (pH 8) and 400 mg/ml of proteinase K). DNA obtained after saturated salt precipitation (5 M NaCl) was further
precipitated using ice-cold isopropanol. DNA pellet was washed with 70% ethanol. Purified DNA was dried and resuspended in
200 mL of distilled water. 1 mL of DNA was used for genotyping as previously reported.28,29 Primers used for genotyping are listed
in Table S5. Amplification products for Lep alleles were incubated with 10% cutsmart enzyme buffer and 1% of DdeI restriction
enzyme overnight at 37C before analysis on agarose gels.
qRT-PCR
For qRT-PCR, total RNA was extracted from frozen pancreas or different cell lines as described previously24,28,29 and qRT-PCR was
performed with primers described in Table S6.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Statistical analyseswere performed usingGraphPadPrism V5.0 software. Statistical significance (p) (p% 0.05 = *, p% 0.01 = ** and p
% 0.001 = ***) between the means of two groups was determined using unpaired two-tailed Student’s t test, two-way ANOVA,
Mantel-Cox test, Mann Whitney test or linear regression analysis as indicated in the Figure legends. Results are expressed as the
mean value ±Standard Error of theMean (SEM). KaplanMeier curve for the survival analysis of micewas used.WB are representative
of at least three independent experiments. IF, H&E and IHC are representative of at least three independent mice. Quantification of IF,
H&E and IHC are performed in at least three independent mice. In the case of the experiments in vitro, at least three independent
experiments are performed and quantified. For the in vivo experiments, at least three mice per group are used. ‘‘n’’ represents num-
ber of mice or human samples used in each experiment, as indicated in Figure Legends. ‘‘N’’ represents number of independent ex-
periments performed with cells, as indicated in Figure Legends.
Image Analysis
At least six images per slide were taken at 5 – 10 – 20 X magnifications and quantified using color de-convolution, a colocalization
finder and image analysis tools available in ImageJ 1.7v software. Aswell, different macros were developed by the authors to quantify
immunofluorescence.
To quantify the proportion of different cells in the islets, number of positive cells were counted and normalized to total cell number
per islet.
To quantify b cell density, number of nuclei was counted manually and normalized to the area of the islets in mm2.
Scoring Signal in Human Samples
URI and Insulin scoringwas performed as follows: 0 corresponds to no signal in the pancreatic islet (n = 20); 1 toweak signal (n = 23); 2
to moderate signal (n = 25); 3 to robust signal (n = 11); 4 to strong signal (n = 1).
For PDX1 and DNMT1 quantification, percentage of positive nuclei in the pancreatic islets of all the islets present in each sample
were counted.
b cell Mass Quantification
Beta cell mass (mg per pancreas) was calculated by multiplying the average of relative insulin-positive area of 3 slides distant of
50 mm (the percentage of insulin positive area over total pancreas area) by pancreas weight.
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